arrow_back Back to App

PHARA Act: Protecting NIH Medical Research Funding Stability

This act aims to ensure stable funding for important medical research conducted by the National Institutes of Health (NIH). Citizens can be confident that crucial research projects, which may lead to new drugs and therapies, will not be suddenly halted due to lack of funds or changing priorities. This means greater certainty for scientists and potentially faster medical advancements.
Key points
Immediate release and expenditure of all funds for existing NIH grant agreements, ensuring research continuity.
Prohibition of sudden termination of active NIH-funded research, even if program goals or agency priorities change.
Mandatory inclusion of termination clauses in new NIH grant agreements, specifying clear conditions for ending cooperation (e.g., material breach, change in circumstances, mutual agreement), with a 90-day notice requirement and an attempt to amend terms before termination.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_HR_4007
Sponsor: Rep. Watson Coleman, Bonnie [D-NJ-12]
Process start date: 2025-06-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

PHARA Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_4007.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-06-12.

What are the main provisions?

Key points include:

  • Immediate release and expenditure of all funds for existing NIH grant agreements, ensuring research continuity.
  • Prohibition of sudden termination of active NIH-funded research, even if program goals or agency priorities change.
  • Mandatory inclusion of termination clauses in new NIH grant agreements, specifying clear conditions for ending cooperation (e.g., material breach, change in circumstances, mutual agreement), with a 90-day notice requirement and an attempt to amend terms before termination.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Watson Coleman, Bonnie [D-NJ-12].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-22.

CATEGORIES

Health Public Investments